A Double-blind, Placebo-controlled, Randomized, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Japanese Adult Participants
Latest Information Update: 05 Feb 2025
At a glance
- Drugs JNJ 73763989 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 25 Sep 2019 Status changed from recruiting to completed.
- 11 Jul 2019 Status changed from not yet recruiting to recruiting.
- 03 Jul 2019 New trial record